Faculty | Infectious Diseases Division

Pablo Tebas, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania

Attending Physician, Hospital of the University of Pennsylvania

Director and Principal Investigator of the AIDS clinical trial unit research site, University of Pennsylvania

Investigator of the Vaccine Trials Network, University of Pennsylvania

Director of the Developmental Core of the CFAR (Center for AIDS research), University of Pennsylvania Perelman School of Medicine, University of Pennsylvania

Department: Medicine

Contact information

Academic Address: 502 Johnson Pavilion. Infectious Disease office.
Clinical Office: Hospital of the University of Pennsylvania. 3400 Spruce Street. Silverstein Pavilion 3rd floor. Suite D.
Philadelphia, Pa 19104

Office: 215-349-8091
Fax: 215-349-8011

Email:
pablo.tebas@uphs.upenn.edu

Publications

Search PubMed for articles

Links
Search PubMed for articles

Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.

Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.

Certifications
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2004.
American Board of Internal Medicine, Infectious Diseases, 2005.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Tebas, P., June, C., Stein, D., Mitsuyasu, R., Lalezari, J., Wang, S., Lee, G., Giedlin, M., Tang, W., Ando, D.: Digital Droplet (DD) qPCR Allows Quantitation of HIV Proviral DNA in Aviremic HIV+ Subjects on HAART Treated with ZFN CCR5 Modified Autologous CD4 T-cells (SB-728-T). International Conference Antimicrobial Agents and Chemotherapy. Abstract number H-1581 September 2012.

Shamblaw, D., Palella, F., Ruane, P., Tebas, P., Gazzard, B., Fisher, M., van Lunzen, J., Flamm, J., Ebrahimi, R., White, K., Graham, H., Guyer, B., Fralich, T., Chuck, S. K.: Switching to the Single-Tablet Regimen (STR) Emtricitabine/Rilpivirine/Tenofovir DF (FTC/RPV/TDF) from a Ritonavir-boosted Protease Inhibitor (PI+RTV) and Two Nucleoside Reverse Transcriptase Inhibitors Maintains HIV Suppression and is Well Tolerated in HIV-1 Subjects at Week 24 Regardless of Age: SPIRIT Study. International Conference Antimicrobial Agents and Chemotherapy. Abstract number H-556 September 2012.

Amorosa, V., Umbleja, T., Johnson, V., Kang, M., Luetkemeyer, A., Bardin, M., Haas, D., Chung, R., Yesmin, S., Coughlin, K., Martinez, A., Adams, M.B., Alston-Smith, B., Tebas, P., Peters, M.: The addition of nitazoxanide to peginterferon alfa-2a and ribavirin does not significantly improve sustained virologic response in HCV treatment-naïve genotype 1 HIV-1/HCV co-infected subjects: results of ACTG 5269. 19th International AIDS Conference: Abstract no. WEAB0103 July 2012.

Palella, F. , Tebas, P. , Gazzard, B. , Ruane, P., Shamblaw, D. , Flamm, J., Fisher, M. , van Lunzen,J., Ebrahimi, R. , White, K. , Guyer, B. , Graham, H. , Fralich, T. : SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves serum lipids. 19th International AIDS Conference: Abstract no. TUAB0104 July 2012.

Mexas, A., Papasavvas, E., Azzoni, L., Busch, M., Kostman, J., Mounzer, K., Tebas, P., Foulkes, A. S., Montaner, L., O’Doherty, U.: Concurrent Measurements of Total and Integrated HIV DNA Provide Insight into the Mechanism of Reduced Reservoir Size in an Interferon-alpha followed by Structured Treatment Interruption Trial. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#374. March 2012.

Luetkemeyer, A., Umbleja, T., Amorosa, V., Abu Dayyeh, B., Chung, R.T., Kang, M., Bardin, M., Haas, D. W., Tebas, P, Peters, M.: Nitazoxanide May Mitigate the Unfavorable Association between IL28B. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#758. March 2012.

Azzoni, L., Foulkes, A. S., Papasavvas, E., Mexas, A., Mounzer, K., Tebas, P, Jacobson, J. M., O’Doherty, U., Kostman, J., Montaner, L.: Pegylated Interferon-alpha2A Monotherapy Induces Durable Suppression of HIV-1 Replication and Decreased HIV DNA Integration following ART Interruption. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#631. March 2012.

Overton, E, Kitch, D, Tebas, P, Hunt, P, Ribaudo, H, Smurzynski, M, Stein, J, Benson, C.: Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-Accidental Death: ACTG ALLRT Cohort. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#124. March 2012.

June, C., Tebas, P., Stein, D., Mitsuyasu, R., Lalezari, J. , Wang, S., Lee, G., Levine, B., Tang, W. , Ando, D.: Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV-infected Subjects. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#155. March 2012.

Papasavvas, H., Dawany, N., Azzoni, L., Morales, K., Mounzer, K., Tebas, P., Jacobson, J. M., Kostman, J., Showe, L., Montaner, L.: Immune Correlates of Sustained IFN-alpha-mediated Suppression of HIV Replication: Association with IFN-alpha-mediated Signaling and Increased NK Cell Responses. 19th Conference on Retrovirus and Opportunistic Infections. March 5-8 2012. Seattle. Abstract#93. March 2012.